Goodwill Pharma has signed a strategic agreement to transfer the rights to the FORTACELL brand to HEMOFARM STADA, entrusting this reputable pharmaceutical partner with the markets of Serbia, Bosnia and Herzegovina, North Macedonia, Montenegro, and Albania. This decision represents a significant step in the regional expansion of the brand, while simultaneously preserving and further developing its global strategy.
“Our goal is for FORTACELL to become a recognizable brand not only in the region but also on the international market. The decision to transfer regional rights to an experienced partner such as Hemofarm is part of a broader vision to further expand and strengthen the brand globally,” said Zoltan Tamaš, General Manager of Goodwill Pharma.
Commenting on the acquisition, Hemofarm’s General Manager Ronald Zeliger stated that “this represents an important step in Hemofarm’s portfolio expansion and strengthening its position in the supplementation market.”
“I believe that integrating the Fortacell brand will allow us to offer even more comprehensive and innovative solutions to our consumers, supporting their everyday vitality and health. This step is part of our strategy to strengthen our presence in the vitamins and minerals market and create synergy between different product categories,” Zeliger added.
The FORTACELL brand remains under the control of Goodwill Pharma outside the regional countries, with clear plans to enter new markets and develop innovative formulations in cooperation with international expert teams.
“We are proud of everything we have achieved with the FORTACELL brand so far – from building consumer trust to developing top-quality products in accordance with the highest European standards. We believe that this is the right moment to entrust regional development to a reliable partner like Hemofarm while we focus on expanding the brand globally,” added Zoltan Tamaš.